Clinical trials: Pediatric Respiratory Diseases
Asthma
Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma
Stress and anxiety can negatively affect children with asthma. Reducing the stress of asthmatic children and their families may lead to improved asthma care and fewer asthma symptoms in the children.
- Trial name
- ASPIRE (NCT00384813)
- Testing
- Project ASPIRE Home-Based Family Intervention, Project ASPIRE Enhanced Treatment As Usual
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Emory University
Acute Lung Injury
CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Acute lung injury (ALI) is a common, life-threatening complication among pediatric leukemia and lymphoma and hematopoietic stem cell transplant (HSCT) recipients.
- Trial name
- CALIPSO (NCT00999713)
- Testing
- Calfactant
- Where
- 16 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Milton S. Hershey Medical Center
Venous Thromboembolism (VTE), Pulmonary Embolism
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE.
- Conditions
- Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- Trial name
- NCT02798471
- Testing
- Edoxaban, Standard of Care
- Where
- 140 sites in United States, Argentina and 32 more
- Volunteers
- 290 people
- Sponsor
- Daiichi Sankyo
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02914275
- Testing
- Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
- Where
- 39 sites in United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms
- Trial name
- NCT03653364
- Testing
- Baloxavir Marboxil
- Where
- 27 sites in United States, Bulgaria and 7 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Influenza, Human
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, comparator-controlled, multicenter study of QIVc versus a US-licensed comparator QIV in children 6 months through 47 months of age.
- Conditions
- Influenza, Human, Virus Diseases
- Trial name
- NCT04074928
- Testing
- QIVc, Comparator QIV
- Where
- 47 sites in United States
- Volunteers
- 2,414 people, healthy volunteers welcome
- Sponsor
- Seqirus
RESPIRATORY SYNCYTIAL VIRUS (RSV)
A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
The purpose of this study is to learn about the safety and immune activity of the vaccine (called RSVpreF) in children 2 to <18 years of age.
- Trial name
- PICASSO (NCT05900154)
- Testing
- RSVpreF 120 µg, RSVpreF 60 µg
- Where
- 17 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
A Safety, Efficacy, and Tolerability Study of Daily Dosing with Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months with Asthma.
- Trial name
- NCT00809757
- Testing
- Levalbuterol, Levalbuterol UDV TID
- Where
- 46 sites in United States
- Volunteers
- 197 people
- Sponsor
- Sumitomo Pharma America, Inc.
Dysphonia
Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness
This study will examine whether lansoprazole (Prevacid) and dietary control versus dietary control alone will improve pediatric hoarseness symptoms.
- Trial name
- NCT00637416
- Testing
- Lansoprazole
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Kansas Medical Center
Obstructive Sleep Apnea, Respiratory Insufficiency
Study of the Usability and Efficacy of a New Pediatric CPAP Mask
This study will evaluate a newly developed pediatric mask (known as Pixi) on children aged 2-7 using continuous positive airway pressure (CPAP), or Non-invasive ventilation (NIV) treatment.
- Trial name
- NCT01312948
- Testing
- Prototype mask (known as Pixi)
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- ResMed
Coronavirus Disease 2019 (COVID-19)
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination…
- Trial name
- ENDURE (NCT05375760)
- Testing
- AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
- Where
- 16 sites in United States
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
Asthma
Allergens in Inner-City Schools and Childhood Asthma
Asthma is a disease that affects more than 12% of Americans under the age of 18 for over 14 million missed school days per year, and is the number one cause of school absences in America.
- Trial name
- SICAS-1 (NCT01756391)
- Where
- United States
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Asthma
Fall Epidemic Viral Pediatric Study
Study ADA113872 is an exploratory 16-week multi-centre, randomized, double-blind, parallel group study in pediatric subjects, 4 to 11 years of age, with a history of seasonal asthma exacerbation(s).
- Trial name
- NCT01192178
- Testing
- FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID
- Where
- 38 sites in United States
- Volunteers
- 339 people
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2015/2016 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02545543
- Testing
- Seqirus QIV, Comparator QIV
- Where
- 32 sites in United States
- Volunteers
- 2,278 people, healthy volunteers welcome
- Sponsor
- Seqirus
Oxygen Deficiency, Desaturation of Blood
THRIVE Use in Pediatric Populations- Multi Site
THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
- Conditions
- Oxygen Deficiency, Desaturation of Blood, Hypoventilation, Anesthesia; Adverse Effect
- Trial name
- NCT04322994
- Testing
- Transnasal Humidified Rapid-Insufflation Ventilatory Echange
- Where
- 5 sites in United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Stanford University
Asthma, Allergic Rhinitis
Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis
This study will provide the clinicians guidance on the safest combination of inhaled and nasal corticosteroids for children with mild asthma and allergic rhinitis respectively; however, one safety concern is that these products…
- Trial name
- NCT01550471
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- West Penn Allegheny Health System
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Sleep Apnea, Obstructive
Feasibility of Unattended Home Polysomnography and Comparison to In-laboratory Polysomnography in Pediatric Patients
The purpose of the study is: 1) To assess the feasibility of unmonitored polysomnography and 2) to compare apnea hypopnea index (AHI), average SPO2, and SPO2 nadir between unmonitored polysomnography and in-laboratory…
- Trial name
- NCT03473548
- Testing
- Portable sleep monitor, In-laboratory Polysomnography
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Influenza, Human
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
This study is a pediatric dose-ranging study to evaluate the safety and immunogenicity of vaccination with different MF59-adjuvanted H5N1 vaccine formulations.
- Trial name
- NCT04669691
- Testing
- H5N1 antigen combined with MF59 adjuvant
- Where
- 7 sites in Estonia, Philippines
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Seqirus
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals